Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Porri, S; Fluss, J; Plecko, B; Paschke, E; Korff, CM; Kern, I.
Positive Outcome following Early Diagnosis and Treatment of Pyridoxal-5 '-Phosphate Oxidase Deficiency: A Case Report
NEUROPEDIATRICS. 2014; 45(1): 64-68.
Doi: 10.1055/s-0033-1353489
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Paschke Eduard
-
Plecko Barbara
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
Pyridoxal-5'-phosphate oxidase (PNPO) deficiency is a rare autosomal recessive, vitamin-responsive metabolic disorder causing refractory neonatal seizures that respond to the administration of pyridoxal-5'-phosphate (PLP). There are currently few case studies that have documented the functional outcome in PNPO deficiency, which remains poor in the majority of cases. We present the case of a male infant born at 35 weeks gestation who promptly responded to oral administration of PLP, following resistance to common anticonvulsive therapy and to a pyridoxine trial. Neurological outcome at 21 months is favorable and illustrates the importance of standardized vitamin trials in the acute setting of "therapy-resistant" neonatal seizures. Early recognition of PNPO deficiency and appropriate intervention might be associated with a more favorable outcome than initially considered.
Georg Thieme Verlag KG Stuttgart · New York.
- Find related publications in this database (using NLM MeSH Indexing)
-
Brain Diseases, Metabolic - diagnosis
-
Brain Diseases, Metabolic - drug therapy
-
Humans -
-
Hypoxia-Ischemia, Brain - diagnosis
-
Hypoxia-Ischemia, Brain - drug therapy
-
Infant, Premature -
-
Infant, Premature, Diseases - diagnosis
-
Infant, Premature, Diseases - drug therapy
-
Male -
-
Phosphoric Monoester Hydrolases - therapeutic use
-
Pyridoxaminephosphate Oxidase - deficiency
-
Seizures - diagnosis
-
Seizures - drug therapy
-
Treatment Outcome -